Last week’s news that J&J is abandoning their coronary stent business was sad, but provided several lessons about poor product development execution and the need for constant innovation. J&J created ...

Direct-to-consumer drug advertising is coming under fire from another camp. Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial ...

Johnson & Johnson said late Thursday it plans to buy Conor Medsystems for $1.4 billion in cash, a bid by the pharmaceuticals giant to expand its presence in the $6 billion-a-year market for ...

Johnson & Johnson will stop selling drug-coated heart stents, a former profit driver for the diversified healthcare company that has stumbled due to safety concerns and fierce competition from rival ...

Johnson & Johnson's (JNJ) announcement that it is getting out of the drug-eluting stent business-- those are the tiny drug-covered tubes inserted into arteries to prevent strokes -- was blamed by many ...

NEW YORK (Reuters) - Johnson & Johnson will stop selling drug-coated heart stents, a former profit driver for the diversified healthcare company that has stumbled due to safety concerns and fierce ...

As the long-running battle for dominance in the highly-lucrative stent market continues its twists and turns, Johnson & Johnson will be cheered on news that its Cypher stent has come out on top in a ...

CHICAGO (Reuters) - A new independent analysis shows similar risks of blood clots in patients receiving Johnson & Johnson's Cypher stent and Boston Scientific Corp.'s Taxus stent, Boston Scientific ...

Johnson & Johnson moved to consolidate its position in the market for drug-eluting stents with a $1.4 billion offer for Conor Medsystems. Johnson & Johnson moved to consolidate its position in the ...